What Analysts Are Saying About Tilray After Earnings

By Chris Lange Published Aug 11, 10:55AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

What Analysts Are Saying About Tilray After Earnings — © rgbspace / Getty Images

Tilray Inc. (NASDAQ: TLRY) reported its most recent quarterly results after the market closed on Monday, and investors were not happy. Analysts were not entirely sold on results and many took to the sidelines on this cannabis company.

The firm posted a net loss of $0.66 per share and $50.4 million in revenue, compared with consensus estimates that called for a net loss of $0.27 per share and $55.02 million in revenue. The same period of last year reportedly had a net loss of $0.36 per share and $41.11 million in revenue.

Despite a challenging business environment, management said that it generated healthy year-over-year revenue growth, and it significantly reduced the cost structure and cash burn.

Total cannabis kilogram equivalents sold increased 105% to 11,430 kilograms from 5,588 kilograms in the second quarter of 2019. Total cannabis kilogram equivalents sold increased 84% to 10,294 kilograms from 5,588 kilograms in the second quarter of 2019. The increase was primarily due to a one-time bulk transaction associated with the termination of a supply contract.

[nativounit]

Average cannabis net selling price per gram decreased to $2.64 from $4.61 in the second quarter of 2019 and $5.28 in the first quarter of 2020. Average cannabis net cost per gram decreased to $2.06 from $3.86 in the second quarter of 2019 and $3.97 in the first quarter of 2020.

Here’s what a few analysts had to say about Tilray after the report:

Cantor Fitzgerald reiterated a Neutral rating and cut its price target to $7.90 from $8.00.
Northland Securities reiterated a Hold rating.
Oppenheimer reiterated a Hold rating.
Cowen reiterated a Market Perform rating and cut its price target to $8.50 from $9.00.
Piper Sandler reiterated an Overweight rating and cut its price target to $15 from $20.
Benchmark reiterated a Buy rating and cut its price target to $12 from $14.

Tilray stock traded down about 13% to $6.90 on Tuesday, in a 52-week range of $2.43 to $46.25. The consensus price target is $8.81.

The move from Tilray also prompted a small move on the ETFMG Alternative Harvest ETF (NYSEARCA: MJ). The fund was last seen down nearly 1% at $12.85, in a 52-week range of $8.81 to $28.93.

[recirclink id=728251][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.